Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD

A. Romanovskikh, A. Sinopalnikov, S. Ratchina (Moscow, Smolensk, Russian Federation)

Source: Annual Congress 2007 - Miscellaneous lower respiratory tract infections
Session: Miscellaneous lower respiratory tract infections
Session type: Thematic Poster Session
Number: 3919
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Romanovskikh, A. Sinopalnikov, S. Ratchina (Moscow, Smolensk, Russian Federation). Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD. Eur Respir J 2007; 30: Suppl. 51, 3919

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Efficacy of azithromycin in severe asthma from the AMAZES randomised trial
Source: ERJ Open Res, 5 (4) 00056-2019; 10.1183/23120541.00056-2019
Year: 2019

Open-label, randomized, comparative trail of the efficacy of the azithromycin in the 8-week treatment of mild-to-moderate asthma
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007

A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen
Source: Eur Respir J 2001; 18: Suppl. 33, 189s
Year: 2001

Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006

Efficacy of moxifloxacin for treatment of bronchial colonisation in COPD patients: a randomised, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Treatment and care of COPD
Year: 2007

First data about the efficacy of moxifloxacin in the treatment of pulmonary tuberculosis – a prospective, randomised study versus INH
Source: Annual Congress 2003 - Management of tuberculosis and tubercular infection - old and new considerations
Year: 2003

Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018

Analysis of the efficacy of moxifloxacin for the treatment of bronchial colonization in COPD patients using microbial molecular typing: a randomized, double-blind, placebo-controlled study
Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD
Year: 2008

A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial
Source: Eur Respir J, 57 (6) 2003338; 10.1183/13993003.03338-2020
Year: 2021

Pivot trial A multicentre randomised controlled equivalence trial comparing oral amoxycillin and intravenous penicillin for community acquired pneumonia in children
Source: Eur Respir J 2004; 24: Suppl. 48, 714s
Year: 2004

Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011

Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021
Year: 2021

Budesonide versus prednisone in acute wheezing: randomized double-blinded controlled placebo study
Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives
Year: 2008

Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011

Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)
Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021
Year: 2022

Evaluation of moxifloxacin (MXF) as empiric antibiotic therapy of CAP outpatients: A multicenter prospective study
Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Year: 2012

Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009